We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Actavis Group (ACT), the international generic pharmaceutical company, announces
that it has acquired the Czech generic pharmaceutical company Pharma Avalanche.
Ferring Pharmaceutical (China) has celebrated the grand opening of their Zhongshan
manufacturing site located in Zhongshan port on 23 March 2005, the first production
site of this Swiss company in Asia.
Aphton, a biopharmaceutical company focused on the development of immunotherapies
for the treatment of cancer, announced the formal completion of its acquisition
of Igeneon AG, a biopharmaceutical company based in Vienna, Austria.
Pfizer Inc. and Coley Pharmaceutical Group Inc. said
they have entered into an exclusive global license agreement to develop, manufacture
and commercialize Coley's ProMune (CPG 7909), a toll-like receptor 9 (TLR9)
agonist delivered by subcutaneous injection for the potential treatment, control
and prevention of cancers in humans.
U.S. drug industry representatives are applauding the approval of
strict new patent rules in India, but the action has been met with mixed reactions
elsewhere, including from international advocacy groups and within India's own
drug industry.
Solvay's planned $1.3 billion acquisition of France's Fournier Pharma
provides the Belgian firm with a solid performer in the cardiovascular market
and complements the company's existing portfolio with products in the gynaecology,
gastroenterology and psychiatric treatment areas.
Ranbaxy Laboratories has ramped up its filings of HIV antiretroviral
(ARV) agents at the World Health Organisation (WHO) and with U.S. regulators
as part of its commitment to provide these medicines in countries where they
are urgently needed, according to the company.
Adherex Technologies Inc., a biopharmaceutical company with a broad portfolio
of oncology products under development, today announced that Health Canada has
given regulatory clearance for the company's Phase II clinical trial application
(CTA) for ADH-1, the company's lead antitumor biotechnology compound, also known
as Exherin.